Mo1249 The Anti-TNF Agent Infliximab Reverses Inflammatory Sarcopenia in Crohn's Disease

Anti-TNF Withdrawal in Inflammatory Bowel Disease

The introduction of the anti-tumor necrosis factorα agents (anti-TNFα) in clinical practice has greatly advanced the treatment of inflammatory bowel disease. The use of these medications results in durable remission in a subset of patients, preventing surgery and hospitalizations. However, there are some concerns about safety and costs associated with their long-term use. Therefore, anti-TNF wi...

Anti-TNF Treatment in Inflammatory Bowel Disease

Crohn’s disease and ulcerative colitis are chronic inflammatory disorders of the gastrointestinal tract. Although the primary etiological defect stil remains unknown, in the last decade impotant progress has been made concerning the immunological basis of the disease. Genetic, environmental and microbial factors result in repeated activation of mucosal immune response. Tumor necrosis factor alp...

Chronic Inflammatory Demyelinating Polyneuropathy Following Anti-TNF-α Therapy With Infliximab for Crohn's Disease.

We present a 29-year-old male with Crohn's disease who developed chronic inflammatory demyelinating polyneuropathy (CIDP) related to infliximab therapy. He developed lower extremity weakness and dysesthesia 3 weeks after a fourth infliximab dose. Laboratory examination revealed an elevated cerebrospinal fluid protein without pleocytosis. The patient initially responded to plasmapheresis therapy...

Dysregulation of Anti-Inflammatory Annexin A1 Expression in Progressive Crohns Disease

BACKGROUND Development of inflammatory bowel disease (IBD) involves the interplay of environmental and genetic factors with the host immune system. Mechanisms contributing to immune dysregulation in IBD are not fully defined. Development of novel therapeutic strategies is focused on controlling aberrant immune response in IBD. Current IBD therapy utilizes a combination of immunomodulators and b...

Successful Treatment of Refractory Behçet's Disease with the TNF-α Blocker Infliximab